Coq9 Knockout mouse models

Coq9 functions as a lipid-binding partner rather than a catalyst, encoding the mouse ortholog of human COQ9, a protein with a START-like hydrophobic cavity that extracts coenzyme Q intermediates from the inner membrane bilayer and presents them to COQ7, forming a stable complex that is required for the C6-hydroxylation step and for overall stability of complex Q. Recessive human variants, including the well-studied R244X truncation modeled by the Coq9 R239X mouse, cause neonatal encephalomyopathy with demyelination, seizures and renal tubulopathy, accompanied by diagnostic accumulation of demethoxyubiquinone. The allele fork is clear: a knockin truncation reproduces the destabilized COQ7 interaction and progressive encephalopathy suitable for therapeutic testing with 2,4-dihydroxybenzoate, whereas a conditional null with Nes-Cre or renal drivers assigns tissue autonomy. No paralog substitutes for the lipid-binding function, so interpret residual coenzyme Q as dietary uptake, and quantify the demethoxyubiquinone to coenzyme Q ratio as the primary biochemical endpoint.

Coq9 null animals are straightforward to genotype and phenotype when survival is acceptable. They remain a standard background for pharmacology, biomarker, and rescue studies.